1108660-09-8

Basic information

• Product Name: 8-chloro-7-methoxy-4-(4-methoxy-benzyloxy)-2-(3-trifluoromethyl-1H-pyrazol-1-yl)-quinoline
• Synonyms: 8-chloro-7-methoxy-4-(4-methoxy-benzyloxy)-2-(3-trifluoromethyl-1H-pyrazol-1-yl)-quinoline
• CAS NO: 1108660-09-8
• Molecular Weight: 463.843
• Mol File: 1108660-09-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 8-chloro-7-methoxy-4-(4-methoxy-benzyloxy)-2-(3-trifluoromethyl-1H-pyrazol-1-yl)-quinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 8-chloro-7-methoxy-4-(4-methoxy-benzyloxy)-2-(3-trifluoromethyl-1H-pyrazol-1-yl)-quinoline(1108660-09-8)
• EPA Substance Registry System: 8-chloro-7-methoxy-4-(4-methoxy-benzyloxy)-2-(3-trifluoromethyl-1H-pyrazol-1-yl)-quinoline(1108660-09-8)

Safety Data

• Hazardous Substances Data: 1108660-09-8(Hazardous Substances Data)

Upstream product

• 20154-03-4 3-(trifluoromethyl)pyrazole 
• 1108659-41-1 2-chloro-8-methyl-7-methoxy-4-(4-methoxybenzyloxy)quinoline 
• 1108659-32-0 2,4-dichloro-8-methyl-7-methoxyquinoline 
• 19500-02-8 2-methyl-3-methoxyaniline 
• 893620-26-3 2,4,8-trichloro-7-methoxyquinoline 
• 85893-87-4 2-chloro-3-methoxyaniline hydrochloride 
• 1108659-39-7 2,8-dichloro-7-methoxy-4-(4-methoxybenzyloxy)quinoline 

Relevant articles and documents

Discovery and structural diversity of the hepatitis C virus NS3/4A serine protease inhibitor series leading to clinical candidate IDX320

Exploration of the P2 region by mimicking the proline motif found in BILN2061 resulted in the discovery of two series of potent HCV NS3/4A protease inhibitors. X-ray crystal structure of the ligand in contact with the NS3/4A protein and modulation of the

MACROCYCLIC SERINE PROTEASE INHIBITORS

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

MACROCYCLIC SERINE PROTEASE INHIBITORS

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, pharmaceutical compositions comprising such compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.